Tsereton - instructions for use, dose, side effects, contraindications

1 capsule contains as an active substance choline alphoscerate in terms of 100% substance - 400 mg; auxiliary substances: glycerol - 50 mg, purified water - to obtain a mass of contents of 590 mg; composition of the capsule: gelatin, sorbitol, glycerol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide, iron oxide, yellow oxide, purified water.

Description:Capsules gelatinous soft, oval in shape, yellow or yellow with a light brown hue. The contents of capsules are oily transparent colorless or slightly colored liquid.

Pharmacotherapeutic group:Nootropic agent.

ATX: & nbsp

N.07.A.X.02 Choline alfoscerate

Pharmacodynamics:Isotropic agent. Central cholinostimulator, which contains 40.5% of metabolically protected choline. Metabolic protection contributes to the release of choline in | the brain. Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.Increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatial-temporal characteristics: spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases (discirculatory encephalopathy and residual phenomena of cerebral circulation disturbance). Provides a preventive and corrective effect on the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes: participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes. Stimulates dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission, receptor function. Has no effect on the reproductive cycle and does not have a teratogenic, mutagenic effect.

Pharmacokinetics:With parenteral administration (10 mg / kg), Cereton ® predominantly accumulates in the brain, lungs and liver.Absorption - 88%, easily penetrates the blood-brain barrier (with oral intake, the concentration in the brain is 45% of that in the plasma). 85% of the drug is excreted in the form of carbon dioxide, the rest (15%) is excreted by the kidneys and through the intestine.

Indications:

- the recovery period of severe craniocerebral trauma and ischemic stroke, the recovery period of hemorrhagic stroke, with focal hemispheric symptoms or symptoms of brainstem lesions;

- psychoorganic syndrome in the background of degenerative and involuntary changes in the brain;

- cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), including with dementia and encephalopathy;

- senile pseudomelanchia.

Contraindications:

- hypersensitivity to the drug;

- acute stage of hemorrhagic stroke;

- pregnancy;

- the period of breastfeeding;

- children under 18 years (due to lack of data).

Dosing and Administration:In the recovery period of craniocerebral trauma, ischemic or hemorrhagic stroke, Cereton® is prescribed 800 mg in the morning and 400 mg in the afternoon for 6 months.In chronic cerebrovascular insufficiency and the syndromes of dementia, Cereton® is prescribed 400 mg (1 capsule) 3 times a day, preferably after meals, for 3-6 months.

Side effects:Perhaps the appearance of nausea (mainly as a consequence of dopaminergic activation). It does not require cancellation, it is enough to temporarily reduce the dose of the drug. Allergic reactions.

Overdose:Nausea may occur. Treatment: symptomatic therapy.

Interaction:Significant interaction with other drugs has not been identified.

Special instructions:Tsereton ® does not affect the speed of psychomotor reactions.

Form release / dosage:

Capsules 400 mg.

Packaging:

For 14 capsules in a contour mesh package.

For 1 or 2 contour mesh packages along with the instruction for use are placed in a pack of cardboard.

Storage conditions:List B. In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-005608/09

Date of registration:13.07.2009

The owner of the registration certificate:FarmSirma Soteks, ZAO FarmSirma Soteks, ZAO Russia

Manufacturer: & nbsp

NGO EUROPA-BIOFARM, CJSC Russia

Information update date: & nbsp27.09.2015

Illustrated instructions

Instructions

Cereton (Cereton®)